NCT03816345 2026-04-13
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
National Cancer Institute (NCI)
Phase 1 Recruiting
National Cancer Institute (NCI)
Janssen Research & Development, LLC
MoonLake Immunotherapeutics AG
Janssen Pharmaceutica N.V., Belgium
University of Alabama at Birmingham
Janssen Research & Development, LLC
Pfizer
Chinese University of Hong Kong